IL2 and neoplasm: Over the years, IL-2 has been administered in combination with other immunotherapies, such as pembrolizumab (anti-programmed cell death protein 1 antibody) or adoptive cellular therapy (tumor-infiltrating lymphocyte therapy), to reduce severe toxic effects and optimize the therapeutic impact [3,18].